

Almirall appoints Mercedes Diz as VP, Corporate Strategy

- Mercedes Diz will also be joining Almirall's Management Board
- Since she joined Almirall in 2002, Diz has served different positions in the company in areas such as Commercial Operations, Alliance Management & Partners, Marketing, and Licensing & Corporate Development
- Since 2021, Diz has held the position of Senior Director of Corporate Strategy, leading the definition of priorities to achieve company's long-term ambition in medical dermatology

BARCELONA, Spain. November 30, 2022 –Almirall, a global biopharmaceutical company focused on skin health, today announced that **Mercedes Diz will assume the position of VP Corporate Strategy and will join Almirall's Management Board as of December 1.**

Diz joined Almirall in 2002 and, since 2021, has held the position of Senior Director of Corporate Strategy, leading **key strategic processes and projects for Almirall** and defining the priorities to achieve the company's long-term ambition in medical dermatology.

Among her previous roles at Almirall, Diz has been **responsible for managing commercial activities in several affiliates** (Austria, Belgium, Netherlands, Nordics, Poland, Switzerland, and the UK), as well as leading global commercial support functions, including Global Alliance Management & Partners and Licensing & Corporate Development. From 2018 to 2020, Diz successfully led the Global marketing and market access team in charge of the company's Strategic Global Brands. During her tenure, Almirall **launched its first biologic** into the psoriasis market.

Mercedes Diz holds a Biochemistry and Molecular Biology degree from Madrid Autonomous University. Before Almirall, she performed local sales and marketing roles at Pfizer, Allergan, DuPont Pharma and J&J.

"Mercedes has been a key player for the company, leading strategic projects for Almirall. Among them, Mercedes, together with a multidisciplinary team, developed Almirall's Long-Term Strategic Plan, setting the priorities on our journey to become the best Medical Dermatology company," says Carlos Gallardo, Chairman and interim CEO of Almirall. "I am convinced that she will continue to bring great value to Almirall as a new member of the Management Board," he adds.

"I am delighted to take on this new challenge and to be able to continue to contribute to the growth of the company. My appointment also reflects the commitment Almirall has to fostering internal talent development. My appreciation goes out to the company and to the many incredible colleagues and leaders who inspire me every day to pursue our purpose of transforming patients' world", says Mercedes Diz, Almirall's VP Corporate Strategy.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients' needs.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenues in 2021 were 836.5 million euros.

For more information, please visit [almirall.com](https://www.almirall.com)

Media contact Almirall:

Tinkle
Laura Blázquez
lblazquez@tinkle.es
Phone: (+34) 600 430 581

Investors' Relations contact

Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Phone: (+34) 93 291 3087

Corporate Communications contact:

Almirall
Mar Ramírez
mar.ramirez@almirall.com
Phone: (+34) 659614173

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the company considers reasonable. These statements involve risks and uncertainties beyond the control of the company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.